The Cooper Companies, Inc. (COO)
| Market Cap | 13.99B -3.6% |
| Revenue (ttm) | 4.23B +6.1% |
| Net Income | 235.80M -43.1% |
| EPS | 1.18 -42.8% |
| Shares Out | 195.03M |
| PE Ratio | 60.53 |
| Forward PE | 15.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,666,902 |
| Open | 73.10 |
| Previous Close | 73.10 |
| Day's Range | 71.45 - 73.95 |
| 52-Week Range | 58.89 - 89.83 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 80.86 (+12.76%) |
| Earnings Date | Aug 26, 2026 |
About COO
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women’s health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cor... [Read more]
Financial Performance
In fiscal year 2025, The Cooper Companies's revenue was $4.09 billion, an increase of 5.06% compared to the previous year's $3.90 billion. Earnings were $374.90 million, a decrease of -4.44%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for COO stock is "Buy." The 12-month stock price target is $80.86, which is an increase of 12.76% from the latest price.
News
CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcas...
Cooper Cos. Is One of Today's Top S&P 500 Stocks.
The medical device maker gave an update on its troubled CooperSurgical business segment that was music to Wall Street's ears.
The Cooper Companies Earnings Call Transcript: Q2 2026
Record Q2 revenue and EPS growth driven by strong performance in both CooperVision and CooperSurgical, despite Asia-Pac softness and a significant litigation charge. Strategic review of CooperSurgical is advancing, with robust interest and potential for increased share buybacks.
The Cooper Companies Earnings release: Q2 2026
The Cooper Companies released its Q2 2026 earnings on June 4, 2026, summarizing the period's financial results.
The Cooper Companies Slides: Q2 2026
The Cooper Companies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on June 4, 2026.
The Cooper Companies Quarterly report: Q2 2026
The Cooper Companies has published its Q2 2026 quarterly earnings report on June 4, 2026.
CooperCompanies Announces Second Quarter 2026 Results
SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April...
CooperCompanies Appoints Paul Keel to its Board of Directors
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an in...
CooperCompanies Announces Release Date for Second Quarter 2026
SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Th...
CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
New sustainability platform reflects company's commitment to responsible sourcing, moreefficient manufacturing, and offsetting a portion of plastic footprint *†1 ROCHESTER, N.Y., April 9, 2026 /PRNews...
The Cooper Companies Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and earnings growth, driven by product launches, operational efficiencies, and robust cash flow. Guidance for earnings and free cash flow was raised, with continued momentum expected in the Americas and EMEA, while Asia Pac is set to recover in the second half.
The Cooper Companies Quarterly report: Q1 2026
The Cooper Companies has published its Q1 2026 quarterly earnings report on March 5, 2026.
The Cooper Companies Earnings release: Q1 2026
The Cooper Companies released its Q1 2026 earnings on March 5, 2026, summarizing the period's financial results.
The Cooper Companies Slides: Q1 2026
The Cooper Companies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on March 5, 2026.
CooperCompanies Announces First Quarter 2026 Results
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended Janua...
The Cooper Companies Proxy statement: Proxy Filing
The Cooper Companies filed a proxy statement on February 24, 2026, providing details for shareholder voting and corporate governance matters.
The Cooper Companies Proxy statement: Proxy Filing
The Cooper Companies filed a proxy statement on February 24, 2026, providing details for shareholder voting and corporate governance matters.
CooperCompanies Announces Release Date for First Quarter 2026
SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, M...
The Cooper Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Operating in growing contact lens and fertility markets, the company is focused on organic growth, product innovation, and capital efficiency. Strategic review is underway to assess business structure, with strong free cash flow and market share gains expected.
The Cooper Companies Slides: 44th Annual J.P. Morgan Healthcare Conference
The Cooper Companies has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
'Forgotten' stocks that could be 2026 powerhouses
Boyar Research is out with its "Forgotten Forty" list, comprising 40 overlooked stocks that are most likely to outperform this year. Boyar Research president, Jonathan Boyar, joins Market Catalysts ho...
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on We...
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company's Board of Directors (the “Board”) has appointed ...
The Cooper Companies Earnings Call Transcript: Q4 2025
Q4 revenue hit a record $1.065B, up 4.6% year-over-year, with strong MyDay and MiSight growth offsetting softness in China. Fiscal 2026 guidance calls for 4.5–5.5% organic growth and $575–$625M free cash flow, with continued focus on share repurchases and a formal strategic review underway.
The Cooper Companies Annual report: Q4 2025
The Cooper Companies has published its Q4 2025 annual report on December 4, 2025.